腫瘍NGSのインド市場2020-2027:技術別、用途別、製品&サービス別、ワークフロー別、エンドユーザー別

Table of Contents

Chapter 1 Methodology and Scope
1.1 Research Assumptions
1.2 Research Methodology
1.3 Information Procurement
1.4 Information or Data Analysis
1.5 Market Formulation & Validation
1.6 Model
1.7 Market Model
1.8 Global Market: CAGR Calculation
1.9 Objectives
1.9.1 Objective 1
1.9.2 Objective 2
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Landscape
2.4 Market Summary
Chapter 3 INDIA Oncology Next Generation Sequencing Market : Industry outlook
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.1.2 Related/ancillary market outlook
3.2 Penetration & Growth Prospect Mapping, by Technology, 2019
3.3 Next-Generation Sequencing Reimbursement Environment
3.3.1 Role of the commercial payers
3.4 Regulatory and Political Environment
3.5 Market Dynamics
3.5.1 Market driver analysis
3.5.1.1 Exponentially decreasing costs for genetic sequencing
3.5.1.2 Development of companion diagnostics and personalized medicine
3.5.1.3 Technological advancements in cloud computing and data integration
3.5.1.4 Increasing prevalence of cancer
3.5.2 Market restraint analysis
3.5.2.1 Lack of computational efficiency for data management
3.5.2.2 Challenges associated with NGS implementation
3.5.3 Market opportunity analysis
3.5.3.1 Efforts taken to develop genomic databases for the Indian population
3.6 Business Environment Analysis
3.6.1 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
3.6.2 Porter’s Five Forces Analysis
3.7 Impact of COVID-19 Pandemic
3.7.1 Impact on the supply chain
3.7.2 Role of NGS to combat COVID-19 outbreak
3.7.3 Key Initiatives in India
Chapter 4 India Oncology Next Generation Sequencing Market: Competitive Analysis
4.1 Recent Developments & Impact Analysis, by Key Market Participants
4.2 Company/Competition Categorization
4.3 Major Deals & Strategic Alliances Analysis
4.3.1 Mergers & acquisitions
4.3.2 Licensing, partnership Joint ventures, & collaborations
4.4 Market Entry Strategies
Chapter 5 Technology Movement Analysis
5.1 India Oncology NGS Market: Technology Movement Analysis
5.2 Whole Genome Sequencing
5.2.1 Market estimates and forecast, 2016 – 2027 (USD Million)
5.3 Whole Exome Sequencing
5.3.1 Market estimates and forecast, 2016 – 2027 (USD Million)
5.4 Targeted & Gene Panel Sequencing
5.4.1 Market estimates and forecast, 2016 – 2027 (USD Million)
5.4.2 Amplicon-based
5.4.2.1 Market estimates and forecast, 2016 – 2027 (USD Million)
5.4.3 Hybridization-based
5.4.3.1 Market estimates and forecast, 2016 – 2027 (USD Million)
Chapter 6 Application Movement Analysis
6.1 India Oncology NGS Market: Application Movement Analysis
6.2 Diagnostics and Screening
6.2.1 Market estimates and forecast, 2016 – 2027 (USD Million)
6.2.2 Screening
6.2.2.1 Market estimates and forecast, 2016 – 2027 (USD Million)
6.2.2.2 Sporadic Cancer Screening
6.2.2.2.1 Market estimates and forecast, 2016 – 2027 (USD Million)
6.2.2.3 Inherited Cancer Screening
6.2.2.3.1 Market estimates and forecast, 2016 – 2027 (USD Million)
6.2.3 Companion Diagnostics (CDx)
6.2.3.1 Market estimates and forecast, 2016 – 2027 (USD Million)
6.2.4 Other Diagnostics
6.2.4.1 Market estimates and forecast, 2016 – 2027 (USD Million)
6.3 Research Studies
6.3.1 Market estimates and forecast, 2016 – 2027 (USD Million)
Chapter 7 Product & Service Movement Analysis
7.1 Market: Product & Service Movement Analysis
7.2 NGS Platforms and Related Products
7.2.1 Market estimates and forecast, 2016 – 2027 (USD Million)
7.2.2 Panels
7.2.2.1 Market estimates and forecast, 2016 – 2027 (USD Million)
7.2.3 Consumables
7.2.3.1 Market estimates and forecast, 2016 – 2027 (USD Million)
7.2.4 Platforms
7.2.4.1 Market estimates and forecast, 2016 – 2027 (USD Million)
7.3 NGS Services
7.3.1 Market estimates and forecast, 2016 – 2027 (USD Million)
Chapter 8 Workflow Movement Analysis
8.1 India Oncology NGS Market: Workflow Movement Analysis
8.2 Pre-Sequencing
8.2.1 Market estimates and forecast, 2016 – 2027 (USD Million)
8.2.2 NGS Library Preparation Kits
8.2.2.1 Market estimates and forecast, 2016 – 2027 (USD Million)
8.2.3 Semi-automated Library Preparation
8.2.3.1 Market estimates and forecast, 2016 – 2027 (USD Million)
8.2.4 Automated Library Preparation
8.2.4.1 Market estimates and forecast, 2016 – 2027 (USD Million)
8.2.5 Clonal Amplification
8.2.5.1 Market estimates and forecast, 2016 – 2027 (USD Million)
8.3 Sequencing
8.3.1 Market estimates and forecast, 2016 – 2027 (USD Million)
8.4 NGS Data Analysis
8.4.1 Market estimates and forecast, 2016 – 2027 (USD Million)
8.4.2 NGS primary data analysis
8.4.2.1 Market estimates and forecast, 2016 – 2027 (USD Million)
8.4.3 NGS secondary data analysis
8.4.3.1 Market estimates and forecast, 2016 – 2027 (USD Million)
8.4.4 NGS tertiary data analysis
8.4.4.1 Market estimates and forecast, 2016 – 2027 (USD Million)
Chapter 9 End-use Movement Analysis
9.1 Market: End-use Movement Analysis
9.2 Academic Research
9.2.1 Market estimates and forecast, 2016 – 2027 (USD Million)
9.3 Clinical Research
9.3.1 Market estimates and forecast, 2016 – 2027 (USD Million)
9.4 Hospitals & Clinics
9.4.1 Market estimates and forecast, 2016 – 2027 (USD Million)
9.5 Pharma & Biotech Entities
9.5.1 Market estimates and forecast, 2016 – 2027 (USD Million)
9.6 Other Users
9.6.1 Market estimates and forecast, 2016 – 2027 (USD Million)
Chapter 10 Competitive Landscape
10.1 Company Profiles
10.1.1 Illumina, Inc.
10.1.1.1 Company Overview
10.1.1.2 Financial Performance
10.1.1.3 Product Benchmarking
10.1.1.4 Strategic Initiatives
10.1.2 Genotypic Technology Pvt. Ltd.
10.1.2.1 Company Overview
10.1.2.2 Product Benchmarking
10.1.3 TECAN TRADING AG
10.1.3.1 Company Overview
10.1.3.2 Financial Performance
10.1.3.3 Product Benchmarking
10.1.3.4 Strategic Initiatives
10.1.4 SciGenom Labs Pvt. Ltd.
10.1.4.1 Company Overview
10.1.4.2 Product Benchmarking
10.1.4.3 Strategic Initiatives
10.1.5 Xcelris Labs Ltd. (Xcelris Genomics)
10.1.5.1 Company Overview
10.1.5.2 Product Benchmarking
10.1.6 Eurofins Scientific
10.1.6.1 Company Overview
10.1.6.2 Financial Performance
10.1.6.3 Product Benchmarking
10.1.6.4 Strategic Initiatives
10.1.7 4baseCare
10.1.7.1 Company Overview
10.1.7.2 Financial Performance
10.1.7.3 Product Benchmarking
10.1.7.4 Strategic Initiatives
10.1.8 MedGenome
10.1.8.1 Company Overview
10.1.8.2 Product Benchmarking
10.1.8.3 Strategic Initiatives
10.1.9 Sayre Therapeutics
10.1.9.1 Company Overview
10.1.9.2 Product Benchmarking
10.1.9.3 Strategic Initiatives
10.1.10 Redcliffe Life Sciences Pvt. Ltd.
10.1.10.1 Company Overview
10.1.10.2 Product Benchmarking
10.1.11 Partek Incorporated
10.1.11.1 Company Overview
10.1.11.2 Financial Performance
10.1.11.3 Product Benchmarking
10.1.11.4 Strategic Initiatives
10.1.12 Bio-Rad Laboratories, Inc.
10.1.12.1 Company Overview
10.1.12.2 Financial Performance
10.1.12.3 Product Benchmarking
10.1.12.4 Strategic Initiatives
10.1.13 Myriad Genetics, Inc.
10.1.13.1 Company Overview
10.1.13.2 Financial Performance
10.1.13.3 Product Benchmarking
10.1.13.4 Strategic Initiatives
10.1.14 Hologic, Inc. (Gen-Probe Incorporated)
10.1.14.1 Company Overview
10.1.14.2 Financial Performance
10.1.14.3 Product Benchmarking
10.1.14.4 Strategic Initiatives
10.1.15 Horizon Discovery Group plc
10.1.15.1 Company Overview
10.1.15.2 Financial Performance
10.1.15.3 Product Benchmarking
10.1.15.4 Strategic Initiatives
10.1.16 Vela Diagnostics
10.1.16.1 Company Overview
10.1.16.2 Financial Performance
10.1.16.3 Product Benchmarking
10.1.16.4 Strategic Initiatives
10.1.17 Premas Life Sciences
10.1.17.1 Company Overview
10.1.17.2 Financial Performance
10.1.17.3 Product Benchmarking

グローバル市場調査会社